{"success":true,"data":{"pressRelease":{"id":"126223","rtpr_id":"nGNX6J2v9m","ticker":"ZEAL","exchange":"NASDAQ","all_tickers":["ZEAL","ZELA"],"title":"Zealand Pharma – Notification of holding of treasury shares","author":"Globe Newswire","published_at":"2026-08-24T15:05:00.142Z","article_body":"Company announcement – No. 42 / 2026\n\nZealand Pharma – Notification of holding of treasury shares\n\nCopenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S (\"the Company\" or\n“Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology\ncompany transforming the future of metabolic health, today reports its\nnotification pursuant to Section 31 of the Danish Capital Markets Act relating\nto its holding of treasury shares.\n\nAs of 21 August 2026, the Company holds nominally 3,597,842 treasury shares,\ncorresponding to 5.03% of the total share capital and 5.03% of the total\nvoting rights in Zealand Pharma. In accordance with Section 85 of the Danish\nCompanies Act, the Company cannot exercise any voting rights attached to its\ntreasury shares.\n\nAbout Zealand Pharma\nZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on\nadvancing medicines for obesity and metabolic health. Combining more than 25\nyears of peptide R&D expertise with a proprietary data platform that leverages\nadvanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new\nera in obesity and metabolic health. To date, more than 10 Zealand Pharma\ninvented drug candidates have entered clinical development, of which two\nproducts have reached the market and three candidates are in late-stage\ndevelopment. The Company has collaborations with global pharmaceutical and\nbiotechnology partners for research, development, and commercialization.\nFounded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with\na U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.\n\nContacts\nEric Rojas (Investors)\nVice President, Head of Investor Relations\nZealand Pharma\nEmail: erojas@zealandpharma.com\n\nNeshat Anis Ahmadi (Investors)\nInvestor Relations Manager\nZealand Pharma\nEmail: neahmadi@zealandpharma.com\n\nRachel James-Owens (Media)\nVice President, Corporate Communications and Media Relations\nZealand Pharma\nEmail: rjamesowens@zealandpharma.com\n\nAndreas Hylleberg Mølleskov (Media) \nDirector, External Communications\nZealand Pharma\nEmail: ahylleberg@zealandpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31b5d115-c4a3-4dfd-b20e-d222199c4862)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6J2v9m","title":"Zealand Pharma – Notification of holding of treasury shares","author":"Globe Newswire","ticker":"ZEAL","created":"2026-08-24T15:05:00.142Z","tickers":["ZEAL","ZELA"],"exchange":"NASDAQ","article_body":"Company announcement – No. 42 / 2026\n\nZealand Pharma – Notification of holding of treasury shares\n\nCopenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S (\"the Company\" or\n“Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology\ncompany transforming the future of metabolic health, today reports its\nnotification pursuant to Section 31 of the Danish Capital Markets Act relating\nto its holding of treasury shares.\n\nAs of 21 August 2026, the Company holds nominally 3,597,842 treasury shares,\ncorresponding to 5.03% of the total share capital and 5.03% of the total\nvoting rights in Zealand Pharma. In accordance with Section 85 of the Danish\nCompanies Act, the Company cannot exercise any voting rights attached to its\ntreasury shares.\n\nAbout Zealand Pharma\nZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on\nadvancing medicines for obesity and metabolic health. Combining more than 25\nyears of peptide R&D expertise with a proprietary data platform that leverages\nadvanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new\nera in obesity and metabolic health. To date, more than 10 Zealand Pharma\ninvented drug candidates have entered clinical development, of which two\nproducts have reached the market and three candidates are in late-stage\ndevelopment. The Company has collaborations with global pharmaceutical and\nbiotechnology partners for research, development, and commercialization.\nFounded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with\na U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.\n\nContacts\nEric Rojas (Investors)\nVice President, Head of Investor Relations\nZealand Pharma\nEmail: erojas@zealandpharma.com\n\nNeshat Anis Ahmadi (Investors)\nInvestor Relations Manager\nZealand Pharma\nEmail: neahmadi@zealandpharma.com\n\nRachel James-Owens (Media)\nVice President, Corporate Communications and Media Relations\nZealand Pharma\nEmail: rjamesowens@zealandpharma.com\n\nAndreas Hylleberg Mølleskov (Media) \nDirector, External Communications\nZealand Pharma\nEmail: ahylleberg@zealandpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31b5d115-c4a3-4dfd-b20e-d222199c4862)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-24T15:05:00.179943788Z","server_sent_at_ms":1787583900179},"received_at":"2026-08-24T15:05:00.232Z","source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349951/0/en/zealand-pharma-notification-of-holding-of-treasury-shares.html"},"analysis":{"id":"115165","press_release_id":"126223","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Zealand Pharma disclosed its holding of treasury shares as of August 21, 2026, totaling 3,597,842 shares.\n\nThis amount represents 5.03% of the company's total share capital and 5.03% of the total voting rights.\n\nThe company noted that under the Danish Companies Act, it cannot exercise voting rights attached to these treasury shares.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine treasury share notification filed under Danish Capital Markets Act."},"keyFigures":{"customDimensions":{"treasury_shares":3597842,"share_capital_percent":"5.03%","voting_rights_percent":"5.03%"}},"namedEntities":{"people":[{"name":"Eric Rojas","role":"Vice President, Head of Investor Relations"},{"name":"Neshat Anis Ahmadi","role":"Investor Relations Manager"},{"name":"Rachel James-Owens","role":"Vice President, Corporate Communications and Media Relations"},{"name":"Andreas Hylleberg Mølleskov","role":"Director, External Communications"}],"products":[],"companies":[{"name":"Zealand Pharma A/S","ticker":"ZEAL"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine statutory notification of treasury share holdings pursuant to the Danish Capital Markets Act. No operational or financial events disclosed."},"tickerRelevance":{"others":[],"primary":"ZEAL"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_mid_cap_biotech","eventGravity":"routine_compliance_filing"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Zealand Pharma disclosed its holding of treasury shares as of August 21, 2026, totaling 3,597,842 shares.\n\nThis amount represents 5.03% of the company's total share capital and 5.03% of the total voting rights.\n\nThe company noted that under the Danish Companies Act, it cannot exercise voting rights attached to these treasury shares.","key_figures":{"customDimensions":{"treasury_shares":3597842,"share_capital_percent":"5.03%","voting_rights_percent":"5.03%"}},"named_entities":{"people":[{"name":"Eric Rojas","role":"Vice President, Head of Investor Relations"},{"name":"Neshat Anis Ahmadi","role":"Investor Relations Manager"},{"name":"Rachel James-Owens","role":"Vice President, Corporate Communications and Media Relations"},{"name":"Andreas Hylleberg Mølleskov","role":"Director, External Communications"}],"products":[],"companies":[{"name":"Zealand Pharma A/S","ticker":"ZEAL"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-24T16:16:49.344Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small_mid_cap_biotech","eventGravity":"routine_compliance_filing"}},"durationMs":96657,"modelName":"glm-4.7"}}